#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2018 - 6

Conventional and biological therapy for inflammatory bowel disease

Czech version

Authors: Martin Bortlík 1,2,3
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, ISCARE I. V. F. a. s., Praha 1;  Interní klinika 1. LF UK a ÚVN – Vojenské fakultní nemocnice Praha 2;  Farmakologický ústav 1. LF UK a VFN v Praze 3
Published in: Vnitř Lék 2018; 64(6): 642-653
Category: Reviews

Overview

Crohn’s disease and ulcerative colitis are chronic digestive conditions incurable by medication or surgery, which affect mainly young populations in economically developed countries. A medical treatment includes conventional preparations: aminosalicylates, corticosteroids, immunosuppressive drugs, antibiotics and exceptionally also probiotics, while in not responding patients or those at higher risk of an adverse course a biological treatment is indicated. The most frequently administered biologics are antibodies directed against the tumour-necrosis factor α, which are highly effective, but the length of their application is limited by a loss of efficiency and incidence of adverse effects. The new, more selectively acting biologics include anti-integrin antibodies and interleukin 12/23 antibodies.

Key words:

biological treatment – Crohn’s disease – idiopathic bowel inflammation – medication-based treat­ment – ulcerative colitis

Sources
  1. Burisch J, Pedersen N, Čuković-Čavka S et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63(4): 588–597. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2013–304636>.
  2. Jarkovský J, Benešová K, Hejduk K et al. Epidemiology, hospitalization and migration of patients with IBD under specialized care in the Czech Republic. Gastroent Hepatol 2017; 71(6): 501–509.
  3. Baumgart DC, Sandborn WJ. Crohn‘s disease. Lancet 2012; 380(9853): 1590–1605. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)60026–9>. Erratum in Lancet 2013; 381(9862): 204.
  4. de Souza HS. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opin Gastroenterol 2017; 33(4): 222–229. Dostupné z DOI: <http://dx.doi.org/10.1097/MOG.0000000000000364>.
  5. Gower-Rousseau C, Vasseur F, Fumery M et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis 2013; 45(2): 89–94. Dostupné z DOI: <http://dx.doi.org/10.1016/j.dld.2012.09.005>.
  6. Charpentier C, Salleron J, Savoye G et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014; 63(3): 423–432. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–303864>.
  7. Gower-Rousseau C, Dauchet L, Vernier-Massouille G et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104(8): 2080–2088. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2009.177>.
  8. Stange EF, Travis SP, Vermeire S et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2(1): 1–23. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2007.11.001>.
  9. Lukáš M. Idiopatické střevní záněty: nejistoty, současné znalosti a klinický přístup. Galén: Praha 1998. ISBN 80–85824–79–5.
  10. Bajer L, Kamenář D, Sticová E et al. Idiopatický střevní zánět u pacientů s primární sklerozující cholangitidou – samostatný fenotyp IBD. Gastroent Hepatol 2014; 68(1): 24–35.
  11. Colombel JF, Rutgeerts PJ, Sandborn WJ et al. Adalimumab induces deep remission in patients with Crohn‘s disease. Clin Gastroenterol Hepatol 2014; 12(3): 414–422. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2013.06.019>.
  12. Dignass AU, Bokemeyer B, Adamek H et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7(7): 762–769. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2009.04.004>.
  13. Flourié B, Hagège H, Tucat G et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013; 37(8): 767–775. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.12266>.
  14. Travis SP, Stange EF, Lémann M et al. European evidence based consensus on the diagnosis and management of Crohn‘s disease: current management. Gut 2006; 55(Suppl 1): i16-i35. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2005.081950b>.
  15. Prokopová L, Ďuricová D, Bortlík M et al. [Consensus of the Czech IBD working group]. Guidelines for the administration of aminosalicylates in patients with inflammatory bowel diseases. Gastroent Hepatol 2012; 66(5): 391–400.
  16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2(4947): 1041–1048.
  17. Ardite E, Panés J, Miranda M et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 1998; 124(3): 431–433. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.bjp.0701887>.
  18. Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn‘s disease. Clin Pharmacokinet 2004; 43(12): 803–821. Dostupné z DOI: <http://dx.doi.org/10.2165/00003088–200443120–00003>.
  19. Munkholm P, Langholz E, Davidsen M et al. Frequency of glucocorticoid resistance and dependency in Crohn‘s disease. Gut 1994; 35(3): 360–362.
  20. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn‘s disease: Current management. J Crohns Colitis 2010; 4(1): 28–62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2009.12.002>.
  21. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143(5): 1218–1226. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2012.08.003>.
  22. Cara CJ, Pena AS, Sans M et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004; 10(11): RA247-RA254.
  23. Gabbani T, Deiana S, Lunardi S et al. Safety profile of methotrexate in inflammatory bowel disease. Expert Opin Drug Saf 2016; 15(10): 1427–1437. Dostupné z DOI: <http://dx.doi.org/10.1080/14740338.2016.1218468>.
  24. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47(2–3): 119–125.
  25. Pearson DC, May GR, Fick GH et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123(2): 132–142.
  26. Prefontaine E, Sutherland LR, Macdonald JK et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn‘s disease. Cochrane Database Syst Rev 2009; (1): CD000067. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD000067.pub2>.
  27. Panés J, López-Sanromán A, Bermejo F et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn‘s disease. Gastroenterology 2013; 145(4): 766–774. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2013.06.009>.
  28. Cosnes J, Bourrier A, Laharie D et al. Early administration of azathioprine vs conventional management of Crohn‘s Disease: a randomized controlled trial. Gastroenterology 2013; 145(4): 758–765.e2; quiz e14–5. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2013.04.048>.
  29. Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380(9857): 1909–1915. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)61084–8>.
  30. Gionchetti P, Dignass A, Danese S et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn‘s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis 2017; 11(2): 135–149. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjw169>.
  31. Magro F, Gionchetti P, Eliakim R et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017; 11(6): 649–670. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjx008>.
  32. Gomollón F, Dignass A, Annese V et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn‘s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11(1): 3–25. Dostupné z DOI: <http://dx.doi.org10.1093/ecco-jcc/jjw168>.
  33. Lukáš M. Teoretická východiska a současná klinická praxe. In: Pavelka K (ed). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Grada: Praha 2014: 247–252. ISBN 978–80–247–5048–4.
  34. Lukáš M Obecné principy biologické léčby u IBD. In: Pavelka K (ed). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Grada: Praha 2014: 253–264. ISBN 978–80–247–5048–4.
  35. Derkx B, Taminiau J, Radema S et al. Tumour-necrosis-factor antibody treatment in Crohn‘s disease. Lancet 1993; 342(8864): 173–174.
  36. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136(4): 1182–1197. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2009.02.001>.
  37. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146(1): 96–109. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2013.06.010>.
  38. Lukáš M. Ustekinumab – a new biologic drug for the treatment of Crohn‘s disease. Gastroent Hepatol 2017; 71(1): 36–39.
  39. Lukáš M. Biologická léčba Crohnovy choroby. In: Pavelka K (ed). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Grada: Praha 2014: 277–284. ISBN 978–80–247–5048–4.
  40. Lukáš M Perspektivy biologické léčby u idiopatických střevních zánětů. Gastroent Hepatol 2014; 68(3): 225–229.
  41. Bortlík M, Ďuricová D, Kohout P et al. Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: Third, updated edition | Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: 3. aktualizované vydání. Gastroent Hepatol 2016; 70(1): 11–26.
  42. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn‘s disease: results from a single-centre cohort. Gut 2009; 58(4): 492–500. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2008.155812>.
  43. Peters CP, Eshuis EJ, Toxopeüs FM et al. Adalimumab for Crohn‘s disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis 2014; 8(8): 866–875. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2014.01.012>.
  44. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4(4): 355–366. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2010.04.004>.
  45. Billiet T, Cleynen I, Ballet V et al. Prognostic factors for long-term infliximab treatment in Crohn‘s disease patients: a 20-year single centre experience. Aliment Pharmacol Ther 2016; 44(7): 673–683. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13754>.
  46. Bortlík M. Současný pohled na léčbu perianálních píštělí u nemocných s Crohnovou chorobou. Gastroent Hepatol 2013; 67(1): 25–29.
  47. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn‘s disease. N Engl J Med 2004; 350(9): 876–885.Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa030815>.
  48. Sands BE, Gasink C, Jacobstein D et al. Fistula Healing in Pivotal Studies of Ustekinumab in Crohn‘s Disease. Gastroenterology 2017; 152: S185.
  49. Yarur AJ, Kanagala V, Stein DJ et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn‘s disease. Aliment Pharmacol Ther 2017; 45(7): 933–940. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13970>.
  50. Bouguen G, Levesque BG, Feagan BG et al. Treat to target: a proposed new paradigm for the management of Crohn‘s disease. Clin Gastroenterol Hepatol 2015; 13(6): 1042–1050. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2013.09.006>.
  51. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015; 110(9): 1324–1338. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2015.233>.
  52. Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn‘s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390(10114): 2779–2789. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)32641–7>.
  53. Khanna R, Bressler B, Levesque BG et al. Early combined immunosuppression for the management of Crohn‘s disease (REACT): a cluster randomised controlled trial. Lancet 2015; 386(10006): 1825–1834. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00068–9>.
  54. De Cruz P, Kamm MA, Hamilton AL et al. Crohn‘s disease management after intestinal resection: a randomised trial. Lancet 2015; 385(9976): 1406–1417. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61908–5>.
  55. Ahmed T, Rieder F, Fiocchi C et al. Pathogenesis of postoperative recurrence in Crohn‘s disease. Gut 2011; 60(4): 553–562. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2010.221705>.
  56. Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn‘s disease recurrence after ileal resection. Gastroenterology 2009; 136(2): 441–450. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2008.10.051>.
  57. Herfarth HH. Anti-tumor necrosis factor therapy to prevent Crohn‘s disease recurrence after surgery. Clin Gastroenterol Hepatol 2014; 12(9): 1503–1506. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2014.02.014>.
  58. Regueiro M, Feagan BG, Zou B et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn‘s Disease After Ileocolonic Resection. Gastroenterology 2016; 150(7): 1568–1578. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2016.02.072>.
  59. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn‘s disease. N Engl J Med 2010; 362(15): 1383–1395. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0904492>.
  60. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146(2): 392–400. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2013.10.052>.
  61. Sokol H, Seksik P, Carrat F et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59(10): 1363–1368. <http://dx.doi.org/10.1136/gut.2010.212712>.
  62. Cosnes J, Sokol H, Bourrier A et al. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn‘s disease. Aliment Pharmacol Ther 2016; 44(10): 1102–1113. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13808>.
  63. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn‘s disease: the CHARM trial. Gastroenterology 2007; 132(1): 52–65. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2006.11.041>.
  64. Kopylov U, Al-Taweel T, Yaghoobi M et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn‘s disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8(12): 1632–1641. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2014.07.003>.
  65. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60(6): 780–787. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2010.221127>.
  66. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142(2): 257–265. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2011.10.032>.
  67. Van Assche G, Magdelaine-Beuzelin C, D‘Haens G et al. Withdrawal of immunosuppression in Crohn‘s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134(7): 1861–1868. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2008.03.004>.
  68. Filippi J, Laharie D, Michiels C et al. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. J Crohns Colitis 2015; 9(3): 252–258. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjv001>.
  69. Christophorou D, Funakoshi N, Duny Y et al. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015; 41(7): 603–612. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13102>.
  70. Yarur AJ, Kubiliun MJ, Czul F et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13(6): 1118–1124. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2014.12.026>.
  71. Drobne D, Bossuyt P, Breynaert C et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn‘s disease. Clin Gastroenterol Hepatol 2015; 13(3): 514–521. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2014.07.027>.
  72. Bortlík M. Vedolizumab – A novel anti-integrin antibody with high gastrointestinal selectivity. Gastroent Hepatol 2014; 68(6): 481–483.
  73. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369(8): 699–710. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1215734>.
  74. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn‘s disease. N Engl J Med 2013; 369(8): 711–721. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1215739>.
  75. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn‘s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147(3): 618–627. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2014.05.008>.
  76. Lukáš M. Vedolizumab in the therapy of Crohn‘s disease. Gastroent Hepatol 2015; 69(2): 146–150.
  77. Engel T, Ungar B, Yung DE et al. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. J Crohns Colitis 2018; 12(2): 245–257. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjx143>.
  78. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as Induction and Maintenance Therapy for Crohn‘s Disease. N Engl J Med 2016; 375(20): 1946–1960. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1602773>.
  79. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462–2476. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa050516>.
  80. Lukáš M. Current position and future trends of therapy in ulcerative colitis. Gastroent Hepatol 2013; 67(3): 212–218.
  81. Bortlík M. Biologická léčba ulcerózní kolitidy. In: Pavelka K (ed.) Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Grada: Praha 2014: 265–270. ISBN 978–80–247–5048–4.
  82. Huang X, Lv B, Jin HF et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011; 67(8): 759–766. Dostupné z DOI: <http://dx.doi.org/10.1007/s00228–011–1079–3>.
  83. O’Donnell S, Stempak JM, Steinhart AH et al. Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn’s disease. J Crohns Colitis 2015; 9(10): 830–836. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjv115>.
  84. Sparrow MP. Adalimumab in ulcerative colitis – efficacy, safety and optimization in the era of treat-to target. Expert Opin Biol Ther 2017; 17(5): 613–621. Dostupné z DOI: <http://dx.doi.org/10.1080/14712598.2017.1309390>.
  85. Shealy DJ, Cai A, Staquet K et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs 2010; 2(4): 428–439.
  86. Lukáš M. Vedolizumab v léčbě ulcerózní kolitidy. Gastroent Hepatol 2015; 69(1): 29–32.
  87. Lynch RW, Churchhouse AM, Protheroe A et al. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data. Aliment Pharmacol Ther 2016; 43(11): 1132–1141. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13614>.
  88. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128(7): 1805–1811.
  89. Brandse JF, van den Brink GR, Wildenberg ME et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015; 149(2): 350–355. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2015.04.016>.
  90. Fasanmade AA, Adedokun OJ, Olson A et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48(5): 297–308.
  91. Malíčková K, Bortlík M, Ďuricová D et al. Vliv albuminemie na farmakokinetiku infliximabu u nemocných s idiopatickými střevními záněty. Čes a Slov Gastroent Hepatol 2011; 65(2): 70–74.
  92. Hindryckx P, Novak G, Vande Casteele N et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther 2017; 45(5): 617–630. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13913>.
  93. Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13(2): 330–335. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2014.07.041>.
  94. Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015; 13(2): 336–338. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2014.09.045>.
Labels
Diabetology Endocrinology Internal medicine
Current trends in the diagnosis and treatment of gastroesophageal reflux disease
Therapy for peptic ulcer disease
History of celiac disease
Celiac disease in 2018
Diagnosis of gastrointestinal motility disorders
Diverticular disease: diagnosis and treatment
Familial adenomatous polyposis: complex patient management
The IBD outpatient care in the clinical practice
PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis
Possibilities of therapeutic manipulation of the gut microbiota
Prokinetics and their use in gastroenterology
Colorectal cancer screening
Therapeutic digestive endoscopy I
Therapeutic digestive endoscopy II
Article was published in

Internal Medicine

Issue 6
2018 Issue 6
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#